Research Triangle Park, NC – According to filings with the U.S. Securities and Exchange Commission, Resilient Biotics is raising $7,172,432.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Christopher Belnap played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Resilient Biotics

Developing microbiome-derived, live biotherapeutics for animal health. Resilient Biotics is utilizing big data analytics to design microbiome-based therapeutics and advanced screening methods for prevention and precision treatment of deadly infectious diseases. Our goal is to provide more effective treatment strategies while reducing dependency on antibiotics. Resilient Biotics utilizes deep sequencing and a machine learning-based computational platform to characterize host genotypes, commensal microbial communities, and pathogen strain variants for unprecedented microbiome resolution.

To learn more about Resilient Biotics, visit http://resilientbiotics.com/

Contact:
Christopher Belnap, Chief Executive Officer
717-350-3133
https://www.linkedin.com/in/christopher-belnap-a1731820/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved